Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001903812 | SCV002173623 | uncertain significance | not provided | 2022-05-27 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function output the following: SIFT: "Tolerated"; PolyPhen-2: "Possibly Damaging"; Align-GVGD: "Class C0". The leucine amino acid residue is found in multiple mammalian species, which suggests that this missense change does not adversely affect protein function. This variant has not been reported in the literature in individuals affected with LAMA1-related conditions. This variant is present in population databases (rs766759529, gnomAD 0.05%). This sequence change replaces proline, which is neutral and non-polar, with leucine, which is neutral and non-polar, at codon 2433 of the LAMA1 protein (p.Pro2433Leu). |
Ambry Genetics | RCV004042660 | SCV004895550 | uncertain significance | Inborn genetic diseases | 2023-10-10 | criteria provided, single submitter | clinical testing | The c.7298C>T (p.P2433L) alteration is located in exon 51 (coding exon 51) of the LAMA1 gene. This alteration results from a C to T substitution at nucleotide position 7298, causing the proline (P) at amino acid position 2433 to be replaced by a leucine (L). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |